Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 666

1.

Exploring Racial Disparities in Mental Health Diagnoses and Neighborhood Disorganization Among an Urban Cohort of Children and Adolescents with Chronic Medical Conditions.

Glassgow AE, Gerges M, Atkins M, Martin M, Caskey R, Sanders K, Mirza M, Van Voorhees B, Kim S.

Health Equity. 2019 Nov 22;3(1):604-611. doi: 10.1089/heq.2019.0085. eCollection 2019.

2.

An unusual presentation of a large cardiac mass.

Cohen MI, Collazo LR, Firan A, Dangol A, Atkins MB.

Cardiol Young. 2019 Nov 5:1-3. doi: 10.1017/S104795111900249X. [Epub ahead of print]

PMID:
31685077
3.

Total endovascular repair of the aortic arch: initial experience in the Netherlands (Commentary).

Atkins MD, Reardon MJ.

Ann Thorac Surg. 2019 Oct 31. pii: S0003-4975(19)31600-5. doi: 10.1016/j.athoracsur.2019.09.037. [Epub ahead of print] No abstract available.

PMID:
31678473
4.

Retraction: The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells.

Panka DJ, Wang W, Atkins MB, Mier JW.

Cancer Res. 2019 Oct 15;79(20):5459. doi: 10.1158/0008-5472.CAN-19-2621. No abstract available.

PMID:
31615813
5.

FIGNL1 associates with KIF1Bβ and BICD1 to restrict dynein transport velocity during axon navigation.

Atkins M, Gasmi L, Bercier V, Revenu C, Del Bene F, Hazan J, Fassier C.

J Cell Biol. 2019 Oct 7;218(10):3290-3306. doi: 10.1083/jcb.201805128. Epub 2019 Sep 19.

PMID:
31541015
6.

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.

Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi FS, Kirkwood JM, Kluger HM, Larkin J, Postow MA, Ritchings C, Sznol M, Tarhini AA, Wolchok JD, Atkins MB, McDermott DF.

J Clin Oncol. 2019 Dec 10;37(35):3350-3358. doi: 10.1200/JCO.19.00345. Epub 2019 Sep 9.

PMID:
31498030
7.

Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.

Xu W, Puligandla M, Manola J, Bullock AJ, Tamasauskas D, McDermott DF, Atkins MB, Haas NB, Flaherty K, Uzzo RG, Dutcher JP, DiPaola RS, Bhatt RS.

Clin Cancer Res. 2019 Oct 15;25(20):6098-6106. doi: 10.1158/1078-0432.CCR-19-0818. Epub 2019 Aug 30.

PMID:
31471309
8.

A case of checkpoint inhibitor-induced celiac disease.

Alsaadi D, Shah NJ, Charabaty A, Atkins MB.

J Immunother Cancer. 2019 Aug 5;7(1):203. doi: 10.1186/s40425-019-0694-x.

9.

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, McHenry MB, Hosein F, Harbison CT, Grosso JF, Sznol M.

JAMA Oncol. 2019 Jul 25. doi: 10.1001/jamaoncol.2019.2187. [Epub ahead of print]

10.

Parental Attitudes and Beliefs Surrounding Play Among Predominantly Low-income Urban Families: A Qualitative Study.

Shah R, Gustafson E, Atkins M.

J Dev Behav Pediatr. 2019 Oct/Nov;40(8):606-612. doi: 10.1097/DBP.0000000000000708.

PMID:
31335583
11.

Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma.

Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW.

Clin Cancer Res. 2019 Jul 1;25(13):4194. doi: 10.1158/1078-0432.CCR-19-1601. No abstract available.

PMID:
31263033
12.

Management of metastatic cutaneous melanoma: updates in clinical practice.

Schvartsman G, Taranto P, Glitza IC, Agarwala SS, Atkins MB, Buzaid AC.

Ther Adv Med Oncol. 2019 May 22;11:1758835919851663. doi: 10.1177/1758835919851663. eCollection 2019. Review.

13.

Commentary: To OAC or not to OAC? That is the question.

Atkins M, Reardon MJ.

J Thorac Cardiovasc Surg. 2019 May 24. pii: S0022-5223(19)31099-2. doi: 10.1016/j.jtcvs.2019.04.103. [Epub ahead of print] No abstract available.

PMID:
31204140
14.

Commentary: Constant variability.

Atkins M, Reardon MJ.

J Thorac Cardiovasc Surg. 2019 May 24. pii: S0022-5223(19)31098-0. doi: 10.1016/j.jtcvs.2019.04.102. [Epub ahead of print] No abstract available.

PMID:
31204136
15.

Genetic Associations with Indoor Tanning Addiction among non-Hispanic White Young Adult Women.

Mays D, Ahn J, Zhang B, Atkins MB, Goerlitz D, Tercyak KP.

Ann Behav Med. 2019 Jun 11. pii: kaz021. doi: 10.1093/abm/kaz021. [Epub ahead of print]

PMID:
31185074
16.

Magnetic Human Corneal Endothelial Cell Transplant: Delivery, Retention, and Short-Term Efficacy.

Xia X, Atkins M, Dalal R, Kuzmenko O, Chang KC, Sun CB, Benatti CA, Rak DJ, Nahmou M, Kunzevitzky NJ, Goldberg JL.

Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2438-2448. doi: 10.1167/iovs.18-26001.

17.

A Job Well Begun Is Half Done.

Atkins MD, Reardon MJ.

Semin Thorac Cardiovasc Surg. 2019 Autumn;31(3):451-452. doi: 10.1053/j.semtcvs.2019.02.017. Epub 2019 May 21. No abstract available.

PMID:
31125605
18.

The promise of Immuno-oncology: implications for defining the value of cancer treatment.

Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T 2nd, Campbell JD, Allen J, Ferris AE, Schilsky RL, Danielson D, Lichtenfeld JL, House L, Selig WKD.

J Immunother Cancer. 2019 May 17;7(1):129. doi: 10.1186/s40425-019-0594-0.

19.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.

PMID:
31079938
20.

YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells.

White SM, Avantaggiati ML, Nemazanyy I, Di Poto C, Yang Y, Pende M, Gibney GT, Ressom HW, Field J, Atkins MB, Yi C.

Dev Cell. 2019 May 6;49(3):425-443.e9. doi: 10.1016/j.devcel.2019.04.014.

PMID:
31063758
21.

Essential Gene Profiles for Human Pluripotent Stem Cells Identify Uncharacterized Genes and Substrate Dependencies.

Mair B, Tomic J, Masud SN, Tonge P, Weiss A, Usaj M, Tong AHY, Kwan JJ, Brown KR, Titus E, Atkins M, Chan KSK, Munsie L, Habsid A, Han H, Kennedy M, Cohen B, Keller G, Moffat J.

Cell Rep. 2019 Apr 9;27(2):599-615.e12. doi: 10.1016/j.celrep.2019.02.041.

22.

Corrigendum: Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor-Sparing Antiretroviral Therapy in a High-HBV Endemicity Setting.

Abdullahi A, Fopoussi OM, Torimiro J, Atkins M, Kouanfack C, Geretti AM.

Open Forum Infect Dis. 2019 Apr 3;6(4):ofz142. doi: 10.1093/ofid/ofz142. eCollection 2019 Apr.

23.

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.

Voss MH, Bhatt RS, Vogelzang NJ, Fishman M, Alter RS, Rini BI, Beck JT, Joshi M, Hauke R, Atkins MB, Burgess E, Logan TF, Shaffer D, Parikh R, Moazzam N, Zhang X, Glasser C, Sherman ML, Plimack ER.

Cancer. 2019 Jul 15;125(14):2400-2408. doi: 10.1002/cncr.32061. Epub 2019 Apr 5.

PMID:
30951193
24.

Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.

Atkins MB, Tarhini A, Rael M, Gupte-Singh K, O'Brien E, Ritchings C, Rao S, McDermott DF.

Immunotherapy. 2019 May;11(7):617-629. doi: 10.2217/imt-2018-0208. Epub 2019 Mar 11.

25.

Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.

Rapisuwon S, Izar B, Batenchuk C, Avila A, Mei S, Sorger P, Parks JM, Cooper SJ, Wagner D, Zeck JC, Charabaty AJ, Atkins MB.

J Immunother Cancer. 2019 Mar 4;7(1):61. doi: 10.1186/s40425-019-0533-0.

26.

Collaboration with Urban Community Stakeholders: Refining Paraprofessional-led Services to Promote Positive Parenting.

Mehta TG, Lakind D, Rusch D, Walden AL, Cua G, Atkins MS.

Am J Community Psychol. 2019 Jun;63(3-4):444-458. doi: 10.1002/ajcp.12316. Epub 2019 Mar 1.

PMID:
30825221
27.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK.

N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.

28.

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators.

N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.

PMID:
30779529
29.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.

Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM.

Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19.

PMID:
30712316
30.

Choice of first-line therapy in metastatic melanoma.

Gibney GT, Atkins MB.

Cancer. 2019 Mar 1;125(5):666-669. doi: 10.1002/cncr.31774. Epub 2019 Jan 29. No abstract available.

PMID:
30695110
31.

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Pignon JC, Jegede O, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Choueiri TK, Wu CJ, Atkins MB, McDermott DF, Signoretti S.

Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. doi: 10.1158/1078-0432.CCR-18-3206. Epub 2019 Jan 22.

PMID:
30670497
32.

Drosophila Genetics: The Power of Genetic Mosaic Approaches.

Atkins M.

Methods Mol Biol. 2019;1893:27-42. doi: 10.1007/978-1-4939-8910-2_2.

PMID:
30565122
33.

Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.

Tarhini A, McDermott D, Ambavane A, Gupte-Singh K, Aponte-Ribero V, Ritchings C, Benedict A, Rao S, Regan MM, Atkins M.

Immunotherapy. 2019 Mar;11(4):283-295. doi: 10.2217/imt-2018-0168. Epub 2018 Dec 19.

34.

Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor-Sparing Antiretroviral Therapy in a High-HBV Endemicity Setting.

Abdullahi A, Fopoussi OM, Torimiro J, Atkins M, Kouanfack C, Geretti AM.

Open Forum Infect Dis. 2018 Oct 5;5(10):ofy251. doi: 10.1093/ofid/ofy251. eCollection 2018 Oct. Erratum in: Open Forum Infect Dis. 2019 Apr 03;6(4):ofz142.

35.

Opportunities for life course research through the integration of data across Clinical and Translational Research Institutes.

Hanson HA, Hay WW Jr, Tobin JN, Barkin SL, Atkins M, Karagas MR, Dozier AM, Wetmore C, Konstan MW, Heubi JE.

J Clin Transl Sci. 2018 Jun;2(3):156-162. doi: 10.1017/cts.2018.29.

36.

Risk Perceptions for Trauma-Related Research: An Exploratory Study of Undergraduate Student Researchers in Psychology.

Atkins MS, LeGrow C.

J Empir Res Hum Res Ethics. 2018 Dec;13(5):537-545. doi: 10.1177/1556264618805282. Epub 2018 Oct 25.

PMID:
30358480
37.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
38.

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.

Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM.

Clin Genitourin Cancer. 2019 Feb;17(1):1-6. doi: 10.1016/j.clgc.2018.09.005. Epub 2018 Sep 12.

PMID:
30287223
39.

Modulation of the Hippo pathway and organ growth by RNA processing proteins.

Mach J, Atkins M, Gajewski KM, Mottier-Pavie V, Sansores-Garcia L, Xie J, Mills RA, Kowalczyk W, Van Huffel L, Mills GB, Halder G.

Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10684-10689. doi: 10.1073/pnas.1807325115. Epub 2018 Sep 26.

40.

Community Health Workers and Social Proximity: Implementation of a Parenting Program in Urban Poverty.

Gustafson EL, Atkins M, Rusch D.

Am J Community Psychol. 2018 Dec;62(3-4):449-463. doi: 10.1002/ajcp.12274. Epub 2018 Sep 17.

PMID:
30222866
41.

Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.

McDermott DF, Shah R, Gupte-Singh K, Sabater J, Luo L, Botteman M, Rao S, Regan MM, Atkins M.

Qual Life Res. 2019 Jan;28(1):109-119. doi: 10.1007/s11136-018-1984-3. Epub 2018 Sep 6.

PMID:
30191365
42.

Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.

Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, Sabater J, Ritchings C, Aponte-Ribero V, Regan MM, Atkins M.

Immunotherapy. 2018 Oct;10(14):1241-1252. doi: 10.2217/imt-2018-0085. Epub 2018 Sep 3.

43.

Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.

Atkins MB, Tannir NM.

Cancer Treat Rev. 2018 Nov;70:127-137. doi: 10.1016/j.ctrv.2018.07.009. Epub 2018 Jul 20. Review.

44.

Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.

Tan SY, Najita J, Li X, Strazzulla LC, Dunbar H, Lee MY, Seery VJ, Buchbinder EI, Tawa NE, McDermott DF, Lee SJ, Atkins MB, Kim CC.

Melanoma Res. 2019 Feb;29(1):70-76. doi: 10.1097/CMR.0000000000000483.

PMID:
30169431
45.

Reduction in radiation exposure in cardiovascular computed tomography imaging: results from the PROspective multicenter registry on radiaTion dose Estimates of cardiac CT angIOgraphy iN daily practice in 2017 (PROTECTION VI).

Stocker TJ, Deseive S, Leipsic J, Hadamitzky M, Chen MY, Rubinshtein R, Heckner M, Bax JJ, Fang XM, Grove EL, Lesser J, Maurovich-Horvat P, Otton J, Shin S, Pontone G, Marques H, Chow B, Nomura CH, Tabbalat R, Schmermund A, Kang JW, Naoum C, Atkins M, Martuscelli E, Massberg S, Hausleiter J; PROTECTION VI investigators.

Eur Heart J. 2018 Nov 1;39(41):3715-3723. doi: 10.1093/eurheartj/ehy546.

46.

A qualitative study to explore paraprofessionals' role in school-based prevention and early intervention mental health services.

Rusch D, Walden AL, Gustafson E, Lakind D, Atkins MS.

J Community Psychol. 2019 Mar;47(2):272-290. doi: 10.1002/jcop.22120. Epub 2018 Aug 30.

47.

The CCR4-NOT complex is a tumor suppressor in Drosophila melanogaster eye cancer models.

Vicente C, Stirparo R, Demeyer S, de Bock CE, Gielen O, Atkins M, Yan J, Halder G, Hassan BA, Cools J.

J Hematol Oncol. 2018 Aug 25;11(1):108. doi: 10.1186/s13045-018-0650-0.

48.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.

N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

49.

The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management.

Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, Callahan MK, Atkins MB, Sharon E, Antonia SJ, West P, Gravell AE; Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force collaboration.

JNCI Cancer Spectr. 2018 Jul;2(3):pky021. doi: 10.1093/jncics/pky021. Epub 2018 Jul 19. Review.

50.

Implementation of an Enhanced Recovery After Surgery Program Can Change Nutrition Care Practice: A Multicenter Experience in Elective Colorectal Surgery.

Martin L, Gillis C, Atkins M, Gillam M, Sheppard C, Buhler S, Hammond CB, Nelson G, Gramlich L.

JPEN J Parenter Enteral Nutr. 2019 Feb;43(2):206-219. doi: 10.1002/jpen.1417. Epub 2018 Jul 23.

PMID:
30035814

Supplemental Content

Loading ...
Support Center